Compugen Ltd. announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. Michelle joined Compugen in October 2023 as Vice President of Clinical Development.

Most recently Michelle was the Chief Medical Officer of 1 E therapeutics Ltd., a drug development company, creating a novel class of programmable oligonucleotide therapeutics and Aummune Therapeutics Ltd., a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. Michelle was Vice President of Clinical Development at C4 Therapeutics Inc., helping to build up the clinical development group and leading the successful submission of two INDs and initiation of Phase 1 studies. Prior to C4 Therapeutics, Michelle worked in R&D for 9 years at Janssen (now Johnson & Johnson).

During her time there she gained experience in late-stage clinical development, pediatric development and global medical affairs while being a key member of the ibrutinib development team and held positions of increasing responsibility. In addition, Michelle supported key due diligence projects including the acquisition of Momenta Pharmaceuticals Inc., by Johnson & Johnson. Prior to starting in industry in 2011, Michelle trained at Memorial Sloan Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell.

She also spent time at Columbia Presbyterian and Mount Sinai Medical Center in New York. Michelle obtained her medical degree from University of the Witwatersrand, South Africa and is a board-certified pediatric hematologist and oncologist.